A report of two novel NR5A1 mutation families: Possible clinical phenotype of psychiatric symptoms of anxiety and/or depression

Ayuko S. Suwanai, Tomohiro Ishii, Hidenori Haruna, Atsuyuki Yamataka, Satoshi Narumi, Ryuji Fukuzawa, Tsutomu Ogata, Tomonobu Hasegawa

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Objective NR5A1 or steroidogenic factor 1 is a nuclear receptor that plays important roles in the hypothalamus-pituitary-steroidogenic axis. The clinical phenotype of most 46,XY mutation carriers includes disorders of sex development (DSD) without adrenal insufficiency, whereas 46,XX mutation carriers have phenotypes ranging from no symptoms to ovarian insufficiency. Although genetically engineered ventromedial hypothalamus-specific Nr5a1 knockout mice show anxiety behaviour, no psychiatric symptoms have been reported in human NR5A1 mutation carriers. We report clinical and molecular findings for individuals (from two families) with NR5A1 mutations, showing psychiatric symptoms. Design and methods We screened for NR5A1 mutations in a cohort of 34 patients with 46,XY DSD using PCR-based sequencing. Psychiatric symptoms were assessed using mental health assessment tools and structured clinical interviews. Functional properties of detected mutant NR5A1s were studied in silico and in vitro, including three-dimensional (3D) mutation models, subcellular NR5A1 protein localization and transactivation assays. Results We found 2 (46,XY) patients with NR5A1 heterozygous novel mutations (p.D257fs and p.V424del), which were transmitted from their respective mothers. The patients' clinical findings indicated DSD without adrenal insufficiency. Both mothers showed psychiatric symptoms, including excessive anxiety and/or depression. The mother and grandmother of one patient had premature ovarian insufficiency. Functional studies showed altered 3D models of p.V424del and normal subcellular NR5A1 localization and impaired transcriptional activation without dominant-negative effects in both mutations. Conclusions We found 2 (46,XX) NR5A1 mutation carriers with excessive anxiety and/or depression. These results suggest that excessive anxiety and/or depression are possible clinical phenotypes of 46,XX NR5A1 mutations.

Original languageEnglish
Pages (from-to)957-965
Number of pages9
JournalClinical Endocrinology
Volume78
Issue number6
DOIs
Publication statusPublished - 2013 Jun

Fingerprint

Psychiatry
Anxiety
Depression
Phenotype
Mutation
Steroidogenic Factor 1
Disorders of Sex Development
Adrenal Insufficiency
Mothers
Transcriptional Activation
Hypothalamus
XY Disorders of Sex Development 46
Cytoplasmic and Nuclear Receptors
Knockout Mice
Computer Simulation
Mental Health
Interviews
Polymerase Chain Reaction

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

A report of two novel NR5A1 mutation families : Possible clinical phenotype of psychiatric symptoms of anxiety and/or depression. / Suwanai, Ayuko S.; Ishii, Tomohiro; Haruna, Hidenori; Yamataka, Atsuyuki; Narumi, Satoshi; Fukuzawa, Ryuji; Ogata, Tsutomu; Hasegawa, Tomonobu.

In: Clinical Endocrinology, Vol. 78, No. 6, 06.2013, p. 957-965.

Research output: Contribution to journalArticle

Suwanai, Ayuko S. ; Ishii, Tomohiro ; Haruna, Hidenori ; Yamataka, Atsuyuki ; Narumi, Satoshi ; Fukuzawa, Ryuji ; Ogata, Tsutomu ; Hasegawa, Tomonobu. / A report of two novel NR5A1 mutation families : Possible clinical phenotype of psychiatric symptoms of anxiety and/or depression. In: Clinical Endocrinology. 2013 ; Vol. 78, No. 6. pp. 957-965.
@article{a21cd63e6607448db151e5632885ff36,
title = "A report of two novel NR5A1 mutation families: Possible clinical phenotype of psychiatric symptoms of anxiety and/or depression",
abstract = "Objective NR5A1 or steroidogenic factor 1 is a nuclear receptor that plays important roles in the hypothalamus-pituitary-steroidogenic axis. The clinical phenotype of most 46,XY mutation carriers includes disorders of sex development (DSD) without adrenal insufficiency, whereas 46,XX mutation carriers have phenotypes ranging from no symptoms to ovarian insufficiency. Although genetically engineered ventromedial hypothalamus-specific Nr5a1 knockout mice show anxiety behaviour, no psychiatric symptoms have been reported in human NR5A1 mutation carriers. We report clinical and molecular findings for individuals (from two families) with NR5A1 mutations, showing psychiatric symptoms. Design and methods We screened for NR5A1 mutations in a cohort of 34 patients with 46,XY DSD using PCR-based sequencing. Psychiatric symptoms were assessed using mental health assessment tools and structured clinical interviews. Functional properties of detected mutant NR5A1s were studied in silico and in vitro, including three-dimensional (3D) mutation models, subcellular NR5A1 protein localization and transactivation assays. Results We found 2 (46,XY) patients with NR5A1 heterozygous novel mutations (p.D257fs and p.V424del), which were transmitted from their respective mothers. The patients' clinical findings indicated DSD without adrenal insufficiency. Both mothers showed psychiatric symptoms, including excessive anxiety and/or depression. The mother and grandmother of one patient had premature ovarian insufficiency. Functional studies showed altered 3D models of p.V424del and normal subcellular NR5A1 localization and impaired transcriptional activation without dominant-negative effects in both mutations. Conclusions We found 2 (46,XX) NR5A1 mutation carriers with excessive anxiety and/or depression. These results suggest that excessive anxiety and/or depression are possible clinical phenotypes of 46,XX NR5A1 mutations.",
author = "Suwanai, {Ayuko S.} and Tomohiro Ishii and Hidenori Haruna and Atsuyuki Yamataka and Satoshi Narumi and Ryuji Fukuzawa and Tsutomu Ogata and Tomonobu Hasegawa",
year = "2013",
month = "6",
doi = "10.1111/cen.12054",
language = "English",
volume = "78",
pages = "957--965",
journal = "Clinical Endocrinology",
issn = "0300-0664",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - A report of two novel NR5A1 mutation families

T2 - Possible clinical phenotype of psychiatric symptoms of anxiety and/or depression

AU - Suwanai, Ayuko S.

AU - Ishii, Tomohiro

AU - Haruna, Hidenori

AU - Yamataka, Atsuyuki

AU - Narumi, Satoshi

AU - Fukuzawa, Ryuji

AU - Ogata, Tsutomu

AU - Hasegawa, Tomonobu

PY - 2013/6

Y1 - 2013/6

N2 - Objective NR5A1 or steroidogenic factor 1 is a nuclear receptor that plays important roles in the hypothalamus-pituitary-steroidogenic axis. The clinical phenotype of most 46,XY mutation carriers includes disorders of sex development (DSD) without adrenal insufficiency, whereas 46,XX mutation carriers have phenotypes ranging from no symptoms to ovarian insufficiency. Although genetically engineered ventromedial hypothalamus-specific Nr5a1 knockout mice show anxiety behaviour, no psychiatric symptoms have been reported in human NR5A1 mutation carriers. We report clinical and molecular findings for individuals (from two families) with NR5A1 mutations, showing psychiatric symptoms. Design and methods We screened for NR5A1 mutations in a cohort of 34 patients with 46,XY DSD using PCR-based sequencing. Psychiatric symptoms were assessed using mental health assessment tools and structured clinical interviews. Functional properties of detected mutant NR5A1s were studied in silico and in vitro, including three-dimensional (3D) mutation models, subcellular NR5A1 protein localization and transactivation assays. Results We found 2 (46,XY) patients with NR5A1 heterozygous novel mutations (p.D257fs and p.V424del), which were transmitted from their respective mothers. The patients' clinical findings indicated DSD without adrenal insufficiency. Both mothers showed psychiatric symptoms, including excessive anxiety and/or depression. The mother and grandmother of one patient had premature ovarian insufficiency. Functional studies showed altered 3D models of p.V424del and normal subcellular NR5A1 localization and impaired transcriptional activation without dominant-negative effects in both mutations. Conclusions We found 2 (46,XX) NR5A1 mutation carriers with excessive anxiety and/or depression. These results suggest that excessive anxiety and/or depression are possible clinical phenotypes of 46,XX NR5A1 mutations.

AB - Objective NR5A1 or steroidogenic factor 1 is a nuclear receptor that plays important roles in the hypothalamus-pituitary-steroidogenic axis. The clinical phenotype of most 46,XY mutation carriers includes disorders of sex development (DSD) without adrenal insufficiency, whereas 46,XX mutation carriers have phenotypes ranging from no symptoms to ovarian insufficiency. Although genetically engineered ventromedial hypothalamus-specific Nr5a1 knockout mice show anxiety behaviour, no psychiatric symptoms have been reported in human NR5A1 mutation carriers. We report clinical and molecular findings for individuals (from two families) with NR5A1 mutations, showing psychiatric symptoms. Design and methods We screened for NR5A1 mutations in a cohort of 34 patients with 46,XY DSD using PCR-based sequencing. Psychiatric symptoms were assessed using mental health assessment tools and structured clinical interviews. Functional properties of detected mutant NR5A1s were studied in silico and in vitro, including three-dimensional (3D) mutation models, subcellular NR5A1 protein localization and transactivation assays. Results We found 2 (46,XY) patients with NR5A1 heterozygous novel mutations (p.D257fs and p.V424del), which were transmitted from their respective mothers. The patients' clinical findings indicated DSD without adrenal insufficiency. Both mothers showed psychiatric symptoms, including excessive anxiety and/or depression. The mother and grandmother of one patient had premature ovarian insufficiency. Functional studies showed altered 3D models of p.V424del and normal subcellular NR5A1 localization and impaired transcriptional activation without dominant-negative effects in both mutations. Conclusions We found 2 (46,XX) NR5A1 mutation carriers with excessive anxiety and/or depression. These results suggest that excessive anxiety and/or depression are possible clinical phenotypes of 46,XX NR5A1 mutations.

UR - http://www.scopus.com/inward/record.url?scp=84876565264&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876565264&partnerID=8YFLogxK

U2 - 10.1111/cen.12054

DO - 10.1111/cen.12054

M3 - Article

C2 - 23095176

AN - SCOPUS:84876565264

VL - 78

SP - 957

EP - 965

JO - Clinical Endocrinology

JF - Clinical Endocrinology

SN - 0300-0664

IS - 6

ER -